Lixisenatide

Known published concerns and unanswered questions are kept separate so absence of evidence is never presented as reassurance.

Form describes the specific product; route describes how it reaches the body. These are sourced descriptions, not instructions.

Routes shown apply only to the named published or investigational formulation; they are not instructions for use.

Status applies to a product, formulation, route, population, and use. It does not apply to a name in the abstract.

1. Mar 20, 2026

   FDA-approved medicine

   Lixisenatide is an active ingredient in FDA-approved Soliqua 100/33. This assertion is limited to that labeled combination product and does not claim that every stand-alone lixisenatide product is currently marketed.

   Specific form or route not separately published in this record.View source

Organize a conversation with a qualified professional without creating a treatment recommendation, dose, or protocol.

• EvidenceWhich human evidence applies to the exact product, form, route, and use being discussed?
• What remains uncertainWhat is known, and what remains uncertain for this specific context?
• RisksWhich important warnings, common effects, and product-quality concerns should be discussed?
• U.S. statusWhat does the U.S. status cover, and what does it not cover?

These profiles share a topic, pathway, product context, or research question. Related does not mean equivalent.

• PramlintideBoth affect post-meal glucose pathways in clinician-directed diabetes care.

1. 1

   SOLIQUA 100/33 prescribing information

   DailyMed. SOLIQUA 100/33 (insulin glargine and lixisenatide) prescribing information. Revised March 2026.

   National Library of Medicine / Sanofi · Published Mar 20, 2026 · Accessed Jul 22, 2026 · Prescribing information

   Open source